Pharvaris Announces Exciting Clinical Trial Results for Deucrictibant
In a recent announcement from Zug, Switzerland, Pharvaris (Nasdaq: PHVS), a leading biopharmaceutical company focused on revolutionizing treatment for hereditary angioedema (HAE), proudly shared the acceptance of several key abstracts for presentation at the upcoming US HAEA National Summit. This prestigious event, slated for July, will spotlight groundbreaking findings on Deucrictibant, an innovative oral bradykinin B2 receptor antagonist aimed at addressing critical needs of those suffering from HAE.
Key Presentations Scheduled
The upcoming summit will feature a series of significant presentations that underline the efficacy and safety of Deucrictibant in various treatment scenarios for HAE. Below are highlights of the sessions that attendees can look forward to:
Long-Term Safety and Efficacy of Deucrictibant
Dr. Michael E. Manning, M.D., will present a poster detailing the results from the CHAPTER-1 Open-Label Extension Study, which focuses on the long-term safety and efficacy of oral Deucrictibant for prophylaxis in HAE patients. This vital data aims to demonstrate the sustained benefits of the treatment.
Improvement of Quality of Life
Continuing with the presentations, Dr. Manning will also share findings on how long-term prophylactic treatment with Deucrictibant not only stabilizes disease control but also enhances health-related quality of life for individuals battling hereditary angioedema.
Insights from the CHAPTER-3 Phase 3 Trial
Dr. H. Henry Li, M.D., Ph.D., will provide critical insights into the CHAPTER-3 Phase 3 trial design, showcasing the expected efficacy and safety of the Deucrictibant extended-release tablet aimed at preventing hereditary angioedema attacks.
RAPIDe-2 Extension Study Findings
Another key presentation will be delivered by Dr. Marc A. Riedl, M.D., M.S., who will discuss the long-term safety and efficacy results from the RAPIDe-2 extension study focusing on Deucrictibant's effectiveness in treating HAE attacks.
Single-Dose Efficacy Analysis
Dr. Joshua S. Jacobs, M.D., will delve into the durability of response to a single dose of Deucrictibant for on-demand treatment, providing insights on its efficacy in addressing HAE attacks effectively.
Comparative Analysis with Standard Care
Additionally, Dr. Mark D. Scarupa, M.D., will lead a presentation comparing Deucrictibant against standard care methods in HAE management. This analysis promises to shed light on the advantages of adopting Deucrictibant as a primary treatment option.
All posters related to these presentations will be available on the Investors section of the Pharvaris website during the event at: https://ir.pharvaris.com/news-events/events-presentations.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical innovator dedicated to developing novel oral bradykinin B2 receptor antagonists suitable for addressing various bradykinin-mediated angioedema conditions. The company's mission revolves around providing effective treatments that combine the efficacy of injectable therapies with the ease of oral administration. Their pipeline includes pivotal studies for Deucrictibant aimed at both prophylactic and on-demand treatments for HAE.
As Pharvaris continues to gather promising results from Phase 2 studies, they are poised to advance their pivotal Phase 3 studies for the prevention and on-demand treatment of HAE attacks (CHAPTER-3 and RAPIDe-3, respectively).
For more details on their innovative work, visit https://pharvaris.com/.
Frequently Asked Questions
What is Pharvaris focusing on currently?
Pharvaris is concentrating on developing oral bradykinin B2 receptor antagonists to innovate treatment for hereditary angioedema and other bradykinin-mediated diseases.
When will the presentations take place?
The presentations will occur from July 10-13, 2025, during the US HAEA National Summit.
Who will present the results associated with Deucrictibant?
Prominent researchers, including Drs. Michael E. Manning, H. Henry Li, Marc A. Riedl, and Joshua S. Jacobs, will be sharing their insights on Deucrictibant.
Where can the presentation materials be accessed?
Presentation posters will be accessible in the Investors section of Pharvaris's website at the time of their presentations.
What does the CHAPTER-3 trial focus on?
The CHAPTER-3 trial focuses on assessing the efficacy and safety of Deucrictibant for preventing hereditary angioedema attacks in a pivotal Phase 3 study.
